Skip to main content
SpringerLink
Log in

Zanamivir

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Summary

  • ▴ Zanamivir is the first of a new class of selective influenza virus neuraminidase inhibitors. It inhibits both influenza A and influenza B virus replication in vitro.

  • ▴ In the ferret model of influenza, zanamivir reduced viral replication and diminished pyrexia associated with the infection.

  • ▴ Repeated passageof influenza virus in the presence of zanamivir could produce resistance in vitro. However, there have been no changes in sensitivity to zanamivir in any influenza virus isolates from patients receiving zanamivir in clinical trials.

  • ▴ In experimental infection in humans, in which the virus replicates only in the nasal passages, intranasal zanamivir (3.6 to 16mg) prevented infection with influenza virus. A combination of inhaled (10mg) and intranasal (6.4mg) zanamivir for 14 days was effective in preventing influenza in a nursing home setting during an influenza A virus outbreak.

  • ▴ Inhaled zanamivir (10mg) with or without intranasal zanamivir (6.4mg) reduced the time to alleviation of influenza symptoms compared with placebo in patients with confirmed infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Madren LK, Shipman JC, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chem Chemother 1995 Mar; 6: 109–13

    CAS  Google Scholar 

  2. Guay DRP. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging 1994 Jul; 5: 8–19

    Article  PubMed  CAS  Google Scholar 

  3. Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opinion on Therapeutic Patents 1995 Aug; 5: 793–803

    Article  CAS  Google Scholar 

  4. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993 Jul; 37: 1473–9

    Article  PubMed  CAS  Google Scholar 

  5. Bethell RC, Smith PW. Sialidase as a target for inhibitors of influenza virus replication. Expert Opin Invest Drug 1997 Oct; 6: 1501–9

    Article  CAS  Google Scholar 

  6. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5-Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994 Oct; 25: 123–31

    Article  PubMed  CAS  Google Scholar 

  7. Thomas GP, Forsyth M, Penn CR, et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 1994 Aug; 24: 351–6

    Article  PubMed  CAS  Google Scholar 

  8. Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3,-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994 Oct; 38: 2270–5

    Article  PubMed  CAS  Google Scholar 

  9. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995 Nov; 39: 2583–4

    Article  PubMed  CAS  Google Scholar 

  10. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-neu5Ac2en and 4-guanidino-neu5Ac2en. Antimicrob Agents Chemother 1996 Jan; 40: 40–6

    PubMed  CAS  Google Scholar 

  11. Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997 Aug; 176 Suppl. 1: S66–8

    Article  PubMed  CAS  Google Scholar 

  12. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997 May; 71: 3385–90

    PubMed  CAS  Google Scholar 

  13. Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir ((GG167) during phase II clinical efficacy trials[abstract no. H-93]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 280

  14. Efthymiopoulos C, Barrington P, Patel J, et al. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando (FL), 265

  15. Newman SP, Brown J, Pickford M, et al. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir; a gamma scintigraphic study [abstract no. H-134]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 237

  16. Hussey E, Hayden F, Grosse C, et al. Serum and urine GG167 concentrations in healthy subjects inoculated experimentally with influenza A virus [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 25

  17. Peterson MC, Sweeney KR, Hsyu PH. Renal disposition and drug screening of GR121167 (GG167) in the isolated perfused rat kidney [abstract]. Pharm Res 1996 Sep; 13 Suppl.: 448

    Google Scholar 

  18. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza A outbreaks [abstract no. H-92]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 230

  19. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996 Jan 24–31; 275: 295–9

    Article  PubMed  CAS  Google Scholar 

  20. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl JMed 1997 Sep 25; 337: 874–80

    Article  CAS  Google Scholar 

  21. Aoki F, Fleming D, Lacey L, et al. Impact of treatment of influenza with zanamivir on patients’ health status, sleep quality, productivity and healthcare use [abstract no. N-15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 384

  22. Rodriguez WJ, Hall CB, Welliver R. et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994; 125: 129–135

    CAS  Google Scholar 

  23. Cass LMR. Efthymiopoulos C, Bye A. An overview of the pharmacokinetics of the neuraminidase inhibitor GG167 [abstract]. Options for the control of influenza III. 1996 May; Cairns

  24. Data on file. Glazo Wellcome

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay Auckland, 10, New Zealand

    Sophie L. Waghorn & Karen L. Goa

Authors
  1. Sophie L. Waghorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen L. Goa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waghorn, S.L., Goa, K.L. Zanamivir. Drugs 55, 721–725 (1998). https://doi.org/10.2165/00003495-199855050-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855050-00015

Keywords

Search

Navigation